This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

CERE-110

Sangamo Biosciences, Inc.

Drug Names(s): CERE-110-NGF, AAV-NGF, AAV2-NGF

Description: CERE-110 uses an AAV2-based vector to deliver the gene for nerve growth factor, a natural brain survival molecule.

Deal Structure: Ceregene and Sangamo
In August 2013, Sangamo announced that it signed a definitive agreement to acquire Ceregene. Under the terms of the definitive agreement Sangamo will issue to the stockholders of Ceregene 100,000 shares of Sangamo's common stock, which represents less than 0.2 percent of Sangamo's total shares outstanding. In addition, Sangamo has agreed to make contingent earn-out payments to the stockholders of Ceregene based upon revenues generated from license or sales transaction of certain existing products of Ceregene. Sangamo will acquire all of Ceregene's preclinical and clinical therapeutic programs including its ongoing double-blind, placebo-controlled Phase II trial to evaluate its NGF-AAV (CERE-110) in Alzheimer's disease (AD) and the proprietary needle device for brain delivery of AAV with supporting regulatory documentation and clinical experience. In October 2013, Sangamo announced that all closing conditions under the merger agreement were satisfied...See full deal structure in Biomedtracker


CERE-110 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug